Literature DB >> 31754890

PET Scan: Nuclear Medicine Imaging in Myositis.

Albert Selva-O'Callaghan1, Albert Gil-Vila2, Marc Simó-Perdigó3, Ernesto Trallero-Araguás4, Marcelo Alvarado-Cárdenas2, Iago Pinal-Fernandez5,6.   

Abstract

PURPOSE OF REVIEW: Positron emission tomography (PET) combined with computed tomography (CT) has proven useful as a cancer screening technique in patients with inflammatory myopathy, mainly dermatomyositis. In this review, we focus on advances in this direction and other potential applications of PET/CT in patients with inflammatory myopathy. RECENT
FINDINGS: Cancer screening by PET/CT seems suitable and cost-effective in patients with myositis. It has also shown value as a hybrid technique for diagnosing myositis versus controls and could be of interest for differentiating between polymyositis and sporadic inclusion body myositis. Quantification of muscle activity by PET/CT seems reliable. Preliminary data suggest that it could also be used to diagnose and measure the activity of the disease in the lung. PET/CT should be in the toolbox of physicians managing patients with myositis. The multiple applications of PET/CT include its value for cancer screening, measuring the activity of the disease in muscle, and helping to differentiate between myositis phenotypes. The possibility to diagnose and monitor inflammatory lung activity remains to be demonstrated in well-designed studies.

Entities:  

Keywords:  Activity; Dermatomyositis; Malignancy; Myositis; PET/CT; Sporadic inclusion body myositis

Year:  2019        PMID: 31754890     DOI: 10.1007/s11926-019-0864-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  52 in total

1.  Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients.

Authors:  Jemima Albayda; Iago Pinal-Fernandez; Wilson Huang; Cassie Parks; Julie Paik; Livia Casciola-Rosen; Sonye K Danoff; Cheilonda Johnson; Lisa Christopher-Stine; Andrew L Mammen
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-11       Impact factor: 4.794

Review 2.  Lung Diseases in Inflammatory Myopathies.

Authors:  Thomas Barba; Sabine Mainbourg; Mouhamad Nasser; Jean-Christophe Lega; Vincent Cottin
Journal:  Semin Respir Crit Care Med       Date:  2019-05-28       Impact factor: 3.119

Review 3.  Molecular imaging of coronary inflammation.

Authors:  Matthieu Pelletier-Galarneau; Terrence D Ruddy
Journal:  Trends Cardiovasc Med       Date:  2018-08-10       Impact factor: 6.677

4.  Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody.

Authors:  Hua Cao; Meng Pan; Yanqing Kang; Qunli Xia; Xia Li; Xiaoqing Zhao; Ruofei Shi; Jianghua Lou; Min Zhou; Masataka Kuwana; Xiaoyi Ding; Jie Zheng
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

5.  Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy.

Authors:  Janneke Van De Vlekkert; Mario Maas; Jessica E Hoogendijk; Marianne De Visser; Ivo N Van Schaik
Journal:  Muscle Nerve       Date:  2015-02       Impact factor: 3.217

6.  Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.

Authors:  Thomas E Lloyd; Lisa Christopher-Stine; Iago Pinal-Fernandez; Eleni Tiniakou; Michelle Petri; Alan Baer; Sonye K Danoff; Katherine Pak; Livia A Casciola-Rosen; Andrew L Mammen
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-01       Impact factor: 4.794

7.  High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody.

Authors:  Yves Allenbach; Jeremy Keraen; Anne-Marie Bouvier; Valérie Jooste; Nicolas Champtiaux; Baptiste Hervier; Yoland Schoindre; Aude Rigolet; Laurent Gilardin; Lucile Musset; Jean-Luc Charuel; Olivier Boyer; Fabienne Jouen; Laurent Drouot; Jeremie Martinet; Tanya Stojkovic; Bruno Eymard; Pascal Laforêt; Antony Behin; Emmanuelle Salort-Campana; Olivier Fain; Alain Meyer; Nicolas Schleinitz; Kuberaka Mariampillai; Aurelie Grados; Olivier Benveniste
Journal:  Brain       Date:  2016-04-17       Impact factor: 13.501

8.  Initial experience with lung-MRI at 3.0T: Comparison with CT and clinical data in the evaluation of interstitial lung disease activity.

Authors:  G Lutterbey; C Grohé; J Gieseke; M von Falkenhausen; N Morakkabati; M P Wattjes; R Manka; D Trog; H H Schild
Journal:  Eur J Radiol       Date:  2006-10-10       Impact factor: 3.528

9.  Detection of inflammatory lesions by f-18 fluorodeoxyglucose positron emission tomography in patients with polymyositis and dermatomyositis.

Authors:  Takayoshi Owada; Reika Maezawa; Kazuhiro Kurasawa; Harutsugu Okada; Satoko Arai; Takeshi Fukuda
Journal:  J Rheumatol       Date:  2012-07-01       Impact factor: 4.666

10.  Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis.

Authors:  Helma Pluk; Bas J A van Hoeve; Sander H J van Dooren; Judith Stammen-Vogelzangs; Annemarie van der Heijden; Helenius J Schelhaas; Marcel M Verbeek; Umesh A Badrising; Snjolaug Arnardottir; Karina Gheorghe; Ingrid E Lundberg; Wilbert C Boelens; Baziel G van Engelen; Ger J M Pruijn
Journal:  Ann Neurol       Date:  2013-03-04       Impact factor: 10.422

View more
  3 in total

1.  Imaging in myositis: MRI or 18F-FDG PET/CT?

Authors:  Ufuk İlgen; Hakan Emmungil
Journal:  Clin Rheumatol       Date:  2022-03-31       Impact factor: 3.650

2.  Novel Muscle Imaging in Inflammatory Rheumatic Diseases-A Focus on Ultrasound Shear Wave Elastography and Quantitative MRI.

Authors:  Matthew Farrow; John Biglands; Abdulrahman M Alfuraih; Richard J Wakefield; Ai Lyn Tan
Journal:  Front Med (Lausanne)       Date:  2020-08-12

3.  Clinical Value of 18F-FDG PET/CT Scan and Cytokine Profiles in Secondary Hemophagocytic Lymphohistiocytosis in Idiopathic Inflammatory Myopathy Patients: A Pilot Study.

Authors:  Junyu Liang; Heng Cao; Bowen Wu; Yinuo Liu; Ye He; Bei Xu; Yiduo Sun; Bingjue Ye; Jin Lin
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.